🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesHas anyone dealt with tirzepatide cardiovascular safety? Page 4

Has anyone dealt with tirzepatide cardiovascular safety?

carlos_SATX Thu, Sep 18, 2025 at 10:20 PM 41 replies 1,657 viewsPage 4 of 9
Dr.GastroMayo
VIP Member
2,345
13,456
Jan 2024
Mayo Clinic, MN
Sep 20, 2025 at 5:53 PM#16

Adding the clinical framing, because it changes how the question reads. The mechanism and the magnitude are separate questions. Agreeing that something happens says nothing about whether it happens enough to act on.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

29 4mike_nyc, VendorMark, COA_Karl and 26 others
Reply Quote Save Share Report
rick_sfbay
Member
289
1,234
Jan 2025
San Francisco, CA
Sep 20, 2025 at 11:24 PM#17
Dr.GastroMayo said:
The mechanism and the magnitude are separate questions.

This matches mine closely enough to be worth saying so out loud.

28 3NicoleRaleigh, james_edin, FranDenver and 25 others
Reply Quote Save Share Report
DataDave
Senior Member
1,678
8,901
Apr 2024
Washington
Online
Sep 21, 2025 at 4:55 AM#18
Dr.GastroMayo said:
The mechanism and the magnitude are separate questions.

Coming at Dr.GastroMayo’s question from a different direction. The useful move here is to separate what is established from what is widely repeated. Those two sets overlap less than the confident tone of most write-ups suggests, and the second set is where nearly all the disagreement on this board comes from.

Worth separating that from cardiovascular outcomes, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

Last edited: Sep 21, 2025 at 5:55 AM
27 2LondonLisa, mike_nyc, VendorMark and 24 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
BiostatsBrad
Member
456
2,345
Jul 2024
Durham, NC
Sep 21, 2025 at 10:26 AM#19

The figures, for anyone assembling their own picture. Practical: whatever you change, write down the date and the reason. In three months the reason is what you will have forgotten, and the reason is what makes the record worth having.

Worth separating that from cardiovascular outcomes, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

26 1james_edin, FranDenver, Dr.BariatricHTX and 23 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Sep 21, 2025 at 3:57 PM#20

Moderator note: the sourcing question belongs in the vendor section and has been split out.

Last edited: Sep 21, 2025 at 5:57 PM
4 4PurityPaulOR, MaxMetOK, MounjBrad and 1 other
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register